{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:07:07Z","timestamp":1791230827844,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134013-CSDG-19-163-01-TBG"],"award-info":[{"award-number":["134013-CSDG-19-163-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R37 CA225655"],"award-info":[{"award-number":["R37 CA225655"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA127003"],"award-info":[{"award-number":["P50 CA127003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011475","name":"Cholangiocarcinoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0118"],"award-info":[{"award-number":["W81XWH-20-1-0118"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.annonc.2022.09.150","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:57:19Z","timestamp":1662692239000},"page":"1269-1283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"J.E.","family":"Berchuck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"DiToro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Baiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.S.","family":"Uson Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.T.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.T.","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Friboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bardeesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Lennerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Kiedrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.09.150_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2022.09.150_bib2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2022.09.150_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.annonc.2022.09.150_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.annonc.2022.09.150_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.09.150_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2022.09.150_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.annonc.2022.09.150_bib8","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2022.09.150_bib9","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.annonc.2022.09.150_bib13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annonc.2022.09.150_bib14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib15","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2022.09.150_bib17","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.annonc.2022.09.150_bib18","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.09.150_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.31850","article-title":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","volume":"125","author":"Narayan","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2022.09.150_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib23","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.09.150_bib26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.annonc.2022.09.150_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib31","first-page":"E2854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.annonc.2022.09.150_bib32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2022.09.150_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2159-8290.CD-17-1009","article-title":"Genomic landscape of cell-free DNA in patients with colorectal cancer","volume":"8","author":"Strickler","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2022.09.150_bib36","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41467-018-05327-w","article-title":"Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer","volume":"9","author":"Nong","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.09.150_bib37","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","article-title":"Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma","volume":"25","author":"Maron","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2022.09.150_bib38","doi-asserted-by":"crossref","first-page":"e2100274","DOI":"10.1200\/PO.21.00274","article-title":"Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy","volume":"6","author":"Uson Junior","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.annonc.2022.09.150_bib40","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.18632\/oncotarget.14844","article-title":"Intratumoral heterogeneity of intrahepatic cholangiocarcinoma","volume":"8","author":"Walter","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2022.09.150_bib41","doi-asserted-by":"crossref","first-page":"a004002","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.annonc.2022.09.150_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2018.02.029","article-title":"Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma","volume":"69","author":"Dong","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.annonc.2022.09.150_bib43","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2022.09.150_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib47","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"10.1016\/j.annonc.2022.09.150_bib48","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib49","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib50","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.09.150_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamaoncol.2018.6286","article-title":"Association of JAK2-V617F mutations detected by solid tumor sequencing with coexistent myeloproliferative neoplasms","volume":"5","author":"Riedlinger","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib52","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","article-title":"Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors","volume":"4","author":"Ptashkin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib53","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMc1701072","article-title":"IDH2 mutation in a patient with metastatic colon cancer","volume":"376","author":"Zhang","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.09.150_bib54","article-title":"Molecular modeling and functional analysis of exome sequencing-derived variants of unknown significance identify a novel, constitutively active FGFR2 mutant in cholangiocarcinoma","volume":"2017","author":"Egan","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib55","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2022.09.150_bib56","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib58","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib59","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib60","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib61","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib63","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.annonc.2022.09.150_bib64","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2022.09.150_bib65","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2022.09.150_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00324","article-title":"Circulating tumor DNA profiling of advanced biliary tract cancers","volume":"3","author":"Mody","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib67","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2159-8290.CD-13-0136","article-title":"Contribution of p53 to metastasis","volume":"4","author":"Powell","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.09.150_bib68","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2022.09.150_bib69","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib70","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.09.150_bib71","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.annonc.2022.09.150_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00017","article-title":"Identification of actionable genomic alterations using circulating cell-free DNA","volume":"3","author":"S\u00e1nchez","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib76","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2019.01.009","article-title":"Molecular analysis of plasma from patients with ROS1-positive non-small cell lung cancer","volume":"14","author":"Dagogo-Jack","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib77","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non\u2013small cell lung cancer patients in routine clinical practice","volume":"13","author":"Park","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib78","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/1878-0261.12789","article-title":"Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing","volume":"14","author":"Cui","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.4950","article-title":"Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"243","author":"Noh","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.annonc.2022.09.150_bib80","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib81","article-title":"Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA","volume":"2018","author":"Dagogo-Jack","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib82","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib83","first-page":"1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2022.09.150_bib84","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2020.38.15_suppl.3545","article-title":"Identification of FGFR2\/3 fusions from clinical cfDNA NGS using a de novo fusion caller","volume":"38","author":"Yablonovitch","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib85","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/s41467-021-22444-1","article-title":"A\u00a0comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection","volume":"12","author":"Larson","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.09.150_bib86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.annonc.2022.09.150_bib87","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.annonc.2022.09.150_bib88","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2022.09.150_bib89","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.09.150_bib90","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41467-021-23394-4","article-title":"Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer","volume":"12","author":"Pereira","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.09.150_bib91","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A\u00a0genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2022.09.150_bib92","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2022.09.150_bib93","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.annonc.2022.09.150_bib94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","volume":"7","author":"Jensen","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2022.09.150_bib95","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.09.150_bib96","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.09.150_bib97","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422041412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422041412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:46:47Z","timestamp":1782485207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422041412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":94,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0923753422041412"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.09.150","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.09.150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}